Objective Bone-marrow stem-cell transplantation has been shown to improve cardiac function in patients with AMI, but the safety of intracoronory infusion of autologous peripheral blood stem-cell(PBSCs) in patients wit...Objective Bone-marrow stem-cell transplantation has been shown to improve cardiac function in patients with AMI, but the safety of intracoronory infusion of autologous peripheral blood stem-cell(PBSCs) in patients with AMI is unknown. For this reason, we observe the feasibility and safety of PBSCs transplantation by intracoronory infusion in such patients.Method Fourty one patients with AMI were allocated to receive Granulocyte Colony-Stimulating Factor (G-CSF:Filgrastim,300 μg) with the dose of 300 μg-600 μg/day to mobilize the stem cell, and the duration of applying G-CSF was 5 days . On the sixth day, PBSCs were separated by Baxter CS 3000 blood cell separator into suspend liquid 57 ml. Then the suspend liquid was infused into the infarct related artery (IRA)by occluding the over the wire balloon and infusing artery through balloon center lumen. In the process of the intracoronary infusion of PBSCs, the complications should be observed, which were arrhythmias including of bradycardia, sinus arrest or atrial ventricular block, premature ventricular beats ,ventricular tachycardia, ventricular fibrillation; and hypotention, etc. Results There were total 10 cases with complications during the intracoronary infusion of PBSCs. The incidence of complications was 24.4%(10/41), including bradycardia is 2.4 %(1/41), sinus arrest or atrial ventricular block is 4.9%(2/41), ventricular fibrillation is 2.4 %( 1/41), hypotention is14.6 % (6 /41).Conclusions In patients with AMI, intracoronary infusion of PBSCs is feasible and safe.展开更多
The effects of pre-irradiation blood transfusion(BT)on survival rateof radiation-burn combinedly injured rats receiving bone marrow transplantation(BMT) were studied. It was found that after 9-11 Gy of radiation was g...The effects of pre-irradiation blood transfusion(BT)on survival rateof radiation-burn combinedly injured rats receiving bone marrow transplantation(BMT) were studied. It was found that after 9-11 Gy of radiation was given, the 90-daysurvival rate of the rats receiving BT(72%) and BMT was significantly higher than thatof those receiving BMT only(42%)(P<0.01).In those rats surviving over 100 days,cells of donor type could be found. In the first 30 days of surviving, the number of Tcells was significantly higher in the BMT alone group than in the group of BMT plusBT, but no difference In restoration of B cell was revealed. The findings suggest that BTcould promote the recipient's tolerance to BMT. The effects of BT on BMT are similarto those on skin grafting.展开更多
目的:评估静脉注射氨甲环酸(tranexamic acid,TXA)在减少肺癌脊柱转移瘤患者后路减压手术的围手术期失血量的安全性和有效性。方法:回顾性分析2011年5月~2022年8月期间收治的接受减压手术的肺癌脊柱转移患者68例,年龄63.1±1.3岁,...目的:评估静脉注射氨甲环酸(tranexamic acid,TXA)在减少肺癌脊柱转移瘤患者后路减压手术的围手术期失血量的安全性和有效性。方法:回顾性分析2011年5月~2022年8月期间收治的接受减压手术的肺癌脊柱转移患者68例,年龄63.1±1.3岁,其中男性42例,女性26例。根据患者从开始麻醉到手术30min内是否接受TXA(1g,静脉注射)分为观察组(26例)和对照组(46例)。收集患者资料:一般资料[包括年龄、性别、(American society of Aneshesiologists physical status classification system,ASA)分级、口服抗凝或抗血小板药物的应用情况]、肿瘤相关资料(包括病理类型和系统治疗)、实验室相关资料(包括术前HGB、Hct、PLT、PT、APTT和术后1d Hct)、手术相关资料(包括减压部位、显露节段、手术类型、手术时间、手术当天的输血量、术后引流量和引流管留置时间以及术后住院情况)和术后住院期间下肢静脉血栓相关资料。采用Gross公式计算总失血量。采用t检验、曼-惠特尼U检验和卡方检验比较两组间的差异。结果:两组患者年龄、性别、ASA分级、病理类型、抗凝或抗血小板药物等一般资料和肿瘤相关资料无统计学差异(P>0.05)。观察组患者术前HGB显著性低于对照组(P=0.035),术前Hct、PLT、PT、APTT以及术后1d Hct等资料无统计学差异(P>0.05)。两组患者在手术减压部位、手术方式、手术显露节段和手术时间上无统计学差异(P>0.05)。观察组失血量明显低于对照组[961.3.4(741.5,1810.4)mL vs 1593.5(1170.2,1936.1)mL,P=0.013],输血量明显少于对照组[400(0,800)mL vs 800(400,800)mL,P=0.024]。两组在引流量、引流时间、术后住院时间和术后新发下肢静脉血栓方面无统计学差异(P>0.05)。结论:开始麻醉到手术30min内静脉注射1g TXA能够减少肺癌脊柱转移患者后路减压手术的失血量和输血量。展开更多
文摘Objective Bone-marrow stem-cell transplantation has been shown to improve cardiac function in patients with AMI, but the safety of intracoronory infusion of autologous peripheral blood stem-cell(PBSCs) in patients with AMI is unknown. For this reason, we observe the feasibility and safety of PBSCs transplantation by intracoronory infusion in such patients.Method Fourty one patients with AMI were allocated to receive Granulocyte Colony-Stimulating Factor (G-CSF:Filgrastim,300 μg) with the dose of 300 μg-600 μg/day to mobilize the stem cell, and the duration of applying G-CSF was 5 days . On the sixth day, PBSCs were separated by Baxter CS 3000 blood cell separator into suspend liquid 57 ml. Then the suspend liquid was infused into the infarct related artery (IRA)by occluding the over the wire balloon and infusing artery through balloon center lumen. In the process of the intracoronary infusion of PBSCs, the complications should be observed, which were arrhythmias including of bradycardia, sinus arrest or atrial ventricular block, premature ventricular beats ,ventricular tachycardia, ventricular fibrillation; and hypotention, etc. Results There were total 10 cases with complications during the intracoronary infusion of PBSCs. The incidence of complications was 24.4%(10/41), including bradycardia is 2.4 %(1/41), sinus arrest or atrial ventricular block is 4.9%(2/41), ventricular fibrillation is 2.4 %( 1/41), hypotention is14.6 % (6 /41).Conclusions In patients with AMI, intracoronary infusion of PBSCs is feasible and safe.
文摘The effects of pre-irradiation blood transfusion(BT)on survival rateof radiation-burn combinedly injured rats receiving bone marrow transplantation(BMT) were studied. It was found that after 9-11 Gy of radiation was given, the 90-daysurvival rate of the rats receiving BT(72%) and BMT was significantly higher than thatof those receiving BMT only(42%)(P<0.01).In those rats surviving over 100 days,cells of donor type could be found. In the first 30 days of surviving, the number of Tcells was significantly higher in the BMT alone group than in the group of BMT plusBT, but no difference In restoration of B cell was revealed. The findings suggest that BTcould promote the recipient's tolerance to BMT. The effects of BT on BMT are similarto those on skin grafting.
文摘目的:评估静脉注射氨甲环酸(tranexamic acid,TXA)在减少肺癌脊柱转移瘤患者后路减压手术的围手术期失血量的安全性和有效性。方法:回顾性分析2011年5月~2022年8月期间收治的接受减压手术的肺癌脊柱转移患者68例,年龄63.1±1.3岁,其中男性42例,女性26例。根据患者从开始麻醉到手术30min内是否接受TXA(1g,静脉注射)分为观察组(26例)和对照组(46例)。收集患者资料:一般资料[包括年龄、性别、(American society of Aneshesiologists physical status classification system,ASA)分级、口服抗凝或抗血小板药物的应用情况]、肿瘤相关资料(包括病理类型和系统治疗)、实验室相关资料(包括术前HGB、Hct、PLT、PT、APTT和术后1d Hct)、手术相关资料(包括减压部位、显露节段、手术类型、手术时间、手术当天的输血量、术后引流量和引流管留置时间以及术后住院情况)和术后住院期间下肢静脉血栓相关资料。采用Gross公式计算总失血量。采用t检验、曼-惠特尼U检验和卡方检验比较两组间的差异。结果:两组患者年龄、性别、ASA分级、病理类型、抗凝或抗血小板药物等一般资料和肿瘤相关资料无统计学差异(P>0.05)。观察组患者术前HGB显著性低于对照组(P=0.035),术前Hct、PLT、PT、APTT以及术后1d Hct等资料无统计学差异(P>0.05)。两组患者在手术减压部位、手术方式、手术显露节段和手术时间上无统计学差异(P>0.05)。观察组失血量明显低于对照组[961.3.4(741.5,1810.4)mL vs 1593.5(1170.2,1936.1)mL,P=0.013],输血量明显少于对照组[400(0,800)mL vs 800(400,800)mL,P=0.024]。两组在引流量、引流时间、术后住院时间和术后新发下肢静脉血栓方面无统计学差异(P>0.05)。结论:开始麻醉到手术30min内静脉注射1g TXA能够减少肺癌脊柱转移患者后路减压手术的失血量和输血量。
